A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

Also called NCT07215312

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07215312
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07215312. Randomized; no masking; primary purpose treatment. Start 2025-10-13 (actual); primary completion 2026-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY3938577
Intervention (Drug)
Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07215312
Content hash
54262671e6272268d151e04d118bcbb99bcf2f11d72cb298e4bf266268804511